

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Indiana University Health / Central Indiana Cancer Centers
6845 Rama Drive
Indianapolis, IN 46219

REPORT NUMBER(S) 2013001

2. NRC/REGIONAL OFFICE

Region III
U. S. Nuclear Regulatory Commission
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

3. DOCKET NUMBER(S)

030-35383

4. LICENSE NUMBER(S)

13-32241-01

5. DATE(S) OF INSPECTION

2/28/13 to 3/18/13

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☒ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.



Non-cited violation(s) were discussed involving the following requirement(s):

- ☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Ken Lambert		3/18/13
BRANCH CHIEF	Tamara E. Bloomer		3/18/13

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Indiana University Health / Central Indiana Cancer Centers 6845 Rama Drive Indianapolis, IN 46219 REPORT NUMBER(S) 2013001		2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352	
3. DOCKET NUMBER(S) 030-35383	4. LICENSE NUMBER(S) 13-32241-01	5. DATE(S) OF INSPECTION 2/28/13 to 3/18/13	
6. INSPECTION PROCEDURES USED 87132	7. INSPECTION FOCUS AREAS 3.01-3.07		

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 2231	2. PRIORITY 2	3. LICENSEE CONTACT Yun Wang, Ph.D	4. TELEPHONE NUMBER (317) 948-1949
--------------------------------	----------------------	---	---

- ☒ Main Office Inspection Next Inspection Date: 3/1/2015
- ☒ Field Office Inspection 10212 Lantern Road, Fishers, IN
- ☐ Temporary Job Site Inspection

PROGRAM SCOPE

IU Health/Central Indiana Cancer Centers is composed of four outpatient facility locations. Since November 2011, the licensee has stopped their nuclear medicine program and performing diagnostic studies. The licensee is authorized to transport the Ir-192 mobile HDR unit between the four facilities; however, treatments are only being conducted at the Indianapolis (main address) and Fishers, IN locations. Although authorized, licensed activities at the Avon field location have not begun as of this inspection. Additionally, there is a pending NRC license amendment request to close the radiation therapy department at the County Line Rd. Indianapolis location. The licensee mainly performs breast and vaginal HDR treatments with a small number of prostate treatments. The sources are changed in the HDR unit every 3-4 months and is locked and stored in it's own room, or in a shared Linear Accelerator room. Prior to the nuclear medicine department closing and since the last inspection in July 2011, there have been approximately 7 Sm-153 Quadramet, 6 Y-90 Zevallin, and 38 I-131 treatments.

Performance Observations

There were no HDR treatments to observe at the time of the inspection, but interviews with licensee staff revealed an adequate level of understanding of radiation safety procedures. For the HDR program: pretreatment QC checks, emergency procedures, security, and transport of the unit were demonstrated or observed successfully. Approximately 18 written directives since the previous inspection involving HDR treatments were reviewed with no issues identified. Additionally, the inspectors observed the van, shipping documents, and labeling for the mobile HDR unit.

For the nuclear medicine program: package receipt procedures, hot lab inventory, leak test records, quarterly linearity checks, daily surveys, and disposal logs and procedures were demonstrated or observed successfully. Approximately 15 written directives since the last inspection for I-131, Sm-153, and Y-90 were reviewed with no identified issues.

Personal dosimetry records reviewed for December 2012 indicated a whole-body reading of 40mrem respectively. The most recent (1/22/13) whole-body reading was 121mrem respectively. Independent measurements taken on the surface of the HDR unit revealed a reading of about 0.01mrem/hr.